AVITA Medical, Inc.
NASDAQ:RCELMedical - Devices
+$0.00 today
- Market cap
- $418.11M
- Beta
- 1.86
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$148.45
Volume 0.72M
Average 0.24M
RCEL Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
AVITA Medical, Inc.NASDAQ: RCEL
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q1 FY2026 accounts receivables of $799K (cash outflow) rose 215.8% year over year, ahead of the +162.7% change in trailing-twelve-month accounts receivables. Sequentially, it rose 886.4% from the prior quarter.
Context
- Accounts receivables amounted to 5.1% of revenue in FY2025, down 1.4 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +215.8% holds above the trailing-twelve-month pace of +162.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 3.63M USD
- Year-over-year change
- +187.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.63M | +187.1% |
| FY2024 | 2024-12-31 | (4.17M) | -26.2% |
| FY2023 | 2023-12-31 | (3.3M) | -235.4% |
| FY2022 | 2022-12-31 | (985K) | +17.4% |
| FY2021 | 2021-12-31 | (1.19M) | — |
Accounts Receivables vs competitors
How RCEL compares with its peers on the latest reported figures
- RCEL's LTM Mar 2026 accounts receivables of $3.09M is the 2nd largest of the 9 companies compared; the peer median is $261K.
- Its year-over-year change of +162.7% is the 4th highest of 7, against a peer median of +85.8%.
- Accounts receivables amounts to 4.3% of revenue for RCEL, versus a peer median of 2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.22M | -27.6% | +17.3% | 6.9% | |
| LTM Mar 2026 | $3.09M | +162.7% | — | 4.3% | |
| LTM Mar 2026 | $2.97M | +199.2% | -46.9% | 2.4% | |
| LTM Mar 2026 | $1.47M | +242.9% | — | 9.6% | |
| LTM Mar 2026 | $1.31M | -404.9% | — | 2.3% | |
| LTM Mar 2026 | $631K | +5158.3% | — | 12.3% | |
| LTM Mar 2026 | $522K | -769.2% | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RCEL) | $261K | +85.8% | -14.8% | 2.4% | |
Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.14M) | (26.67M) | (35.38M) | (61.85M) | (48.59M) |
| Depreciation & Amortization | 969K | 568K | 632K | 1.13M | 2.04M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.33M | 7M | 8.38M | 13.5M | 9.52M |
| Change in Working Capital | (1.73M) | (1.2M) | (6.57M) | (4.68M) | 3.44M |
| Accounts Receivables | (1.19M) | (985K) | (3.3M) | (4.17M) | 3.63M |
| Inventory | (144K) | (371K) | (3.69M) | (2.16M) | (468K) |
| Accounts Payables | 0 | 282K | 809K | 340K | 2.75M |
| Other Working Capital | (391K) | (122K) | (386K) | 1.31M | (2.47M) |
| Other Non-Cash Items | 1.53M | 1.21M | (5.07M) | 2.96M | 2.4M |
| Operating Cash Flow | (18.04M) | (19.09M) | (38.01M) | (48.94M) | (31.2M) |
| Capital Expenditures | (487K) | (525K) | (1.45M) | (9.33M) | (1.74M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (74.36M) | (78.76M) | (24.5M) | (13.31M) |
| Sales of Investments | 0 | 55.56M | 81.81M | 71.2M | 27.5M |
| Other Investing Activities | (49.72M) | (73K) | (66K) | (162K) | (734K) |
| Investing Cash Flow | (50.21M) | (19.33M) | 1.61M | 37.36M | 12.45M |
| Debt Repayment | (11K) | 0 | 38.76M | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 14.14M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 64.08M | 900K | 1.61M | 3.51M | 795K |
| Financing Cash Flow | 64.07M | 900K | 40.37M | 3.51M | 14.94M |
| Effect of Forex Changes | 41.29M | (26K) | (16K) | 0 | 0 |
| Net Change in Cash | 37.11M | (37.55M) | 3.95M | (8.07M) | (3.81M) |
| Free Cash Flow | (18.52M) | (19.62M) | (39.46M) | (58.27M) | (32.93M) |
AVITA Medical, Inc.
NASDAQ:RCEL
Intrinsic Alpha fair value
Locked
Current Price
$16.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.